drugset

Drugs / Hydroxypropyl-β-cyclodextrin

Follow last change Oct 2022 re-read 3 minutes ago

Hydroxypropyl-β-cyclodextrin

also known as 2-hydroxypropyl-β-cyclodextrin · HPβCD · Hydroxypropyl-β-cyclodextrin (HP-β-CD)

Developed for: Niemann-Pick disease, type C1
Investigated by: Cyclo Therapeutics, Inc.

Trials 1

today NCT03893071 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03893071	May 2019 → Mar 2022	Niemann-Pick disease, type C1	Cyclo Therapeutics, Inc.	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2018-04-16	ZyVersa Therapeutics, Inc.	Regulatory Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease stockpr.com ↗ Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today receipt of FDA minutes from the March 12, 2018 Pre-IND meeting regarding development of VAR 200 (2-hydroxypropyl-β-cyclodextrin, or HPβCD) for treatment of Focal Segmental Glomerulosclerosis (FSGS) in adults.

All press releases naming this drug 2 releases

Date	Issuer	Release
2018-10-16	ZyVersa Therapeutics, Inc.	Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-β-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS) stockpr.com ↗
2018-04-16	ZyVersa Therapeutics, Inc.	Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease stockpr.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Hydroxypropyl-β-cyclodextrin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893071 ↗
Known as	2-hydroxypropyl-β-cyclodextrin	“Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral...” PMID 36279795 ↗ Oct 2022
Known as	HPβCD	“Preclinical studies have demonstrated that systemically administered 2-hydroxypropyl-β-cyclodextrin (HPβCD; Trappsol® Cyclo™) restores cholesterol metabolism and homeostasis in...” PMID 36279795 ↗ Oct 2022
Known as	Hydroxypropyl-β-cyclodextrin (HP-β-CD)	“Hydroxypropyl-β-cyclodextrin (HP-β-CD)” NCT03893071 ↗
Action	Restore	“Preclinical studies have demonstrated that systemically administered 2-hydroxypropyl-β-cyclodextrin (HPβCD; Trappsol® Cyclo™) restores cholesterol metabolism and homeostasis in...” PMID 36279795 ↗ Oct 2022